NCT00044512View on ClinicalTrials.gov

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)

Trial Locations (23)

1000

Bruxelles - Brussel

1070

Bruxelles - Brussel

1090

Bruxelles - Brussel

3000

Leuven

9000

Ghent

13005

Marseille

20089

Rozzano

20122

Milan

31096

Haifa

35062

Rennes

37126

Verona

44805

Saint-Herblain

47100

Forlì

49100

Petah Tikva

52621

Tel Litwinsky

56126

Pisa

59020

Lille

64239

Tel Aviv

75020

Paris

76100

Rehovot

90057

Los Angeles

91120

Jerusalem

10021-6007

New York

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY